Hudson Bay Capital Management
ZVSA

Hudson Bay Capital Management’s ZyVersa Therapeutics ZVSA Stock Holding History

Hudson Bay Capital Management’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,000
Closed -$6.99M – 1138
2022
Q3 		$6.99M Hold
2,000
– – 0.06% 266
2022
Q2 		$6.95M Hold
2,000
– – 0.05% 294
2022
Q1 		$6.96M Buy
+2,000
New +$6.92M 0.09% 247

Other funds holding ZVSA

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

Hudson Bay Capital Management's ZVSA Position: Q4 2022 in Review

Hudson Bay Capital Management sold out of ZyVersa Therapeutics (ZVSA) in Q4 2022, closing a stake of 2,000 shares — an estimated $6.99M sold.

Hudson Bay Capital Management first reported a position in ZVSA in Q1 2022 and held it in 3 quarters. The position peaked at $6.99M in Q3 2022. 2 funds tracked by Wall St. Rank hold ZVSA as of Q4 2022.

  • Hudson Bay Capital Management reported no remaining ZyVersa Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Hudson Bay Capital Management sold 2,000 ZyVersa Therapeutics shares in Q4 2022, an estimated $6.99M.
  • Hudson Bay Capital Management first reported a position in ZyVersa Therapeutics in Q1 2022 and held it in 3 quarters.
  • Hudson Bay Capital Management's ZyVersa Therapeutics position peaked at $6.99M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q4 2022.

Based on Hudson Bay Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.